Manage Your Liver
Q:

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer
A:

A study published in the International Liver Congress in 2016 [1] came up with a shocking and unexpected result: Patients with hepatitis c and cirrhosis who use direct antiviral agents (DAA) may begin to develop liver cancer within 2 weeks. Leading researcher Stefano Brillianti, MD stated “The hypothesis is that immune surveillance may be reduced too rapidly,” and “You have an immediate drop in viremia, but also attenuation of inflammation.”

 

The study indicated that patients with a history of hepatocellular carcinoma (liver cancer) have the highest risk of developing tumor after receiving direct-acting antiviral therapy, in addition, the progression is very fast. "Patients with previous hepatocellular carcinoma are, of course, at risk of recurrence anyway," Dr Brillianti said. ”A 30% rate over 3 years from initial surgery or ablation is normal. What was surprising to us was that we were observing 4 cm lesions after 12 weeks." [2]

 

Another research conducted by the University of Barcelona found that out of 58 hepatitis C patients with a history of hepatocellular carcinoma (with complete radiologic response), 55 were cirrhotic before starting direct-acting antiviral therapy. After a median follow-up of 5.7 months, the rate of tumor recurrence was 27.6%, with a median time to recurrence of 3.5 months. This research echoes with the previously mentioned, and suggests that patients with hepatitis C should be closely monitored after treatment with direct-acting antivirals. [3]

 

Stefano Brillanti, MD, went on to say, "This (liver cancer) is a different cancer  than elsewhere in oncology — it is a cancer within an advanced chronic disease — so the prognosis, the life expectancy, is related not only to the liver cancer but also to the liver disease and liver function,”. He added, "If you don't treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.”

 

These two latest research studies once again prove that is it vital to stop inflammation in the liver, and to ensure normal liver function. Whether it is before or after treatment, both hepatitis C patients and patients with hepatocellular carcinoma history should set this as their main objective. Otherwise, even if the virus is successfully removed from the body, normal liver function cannot be guaranteed.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis CLiver CancerHep CAntiviralDDAsDirect acting antiviral treatment
Related Questions
A:
A recent study by Cancer Research reveal that obesity and diabetes increases the risks of liver cancer.   Liver cancer is ranked at sixth most common type of cancer, the number of liver cancers has tripled since the 70s in the United States. Liver cancers is mainly due to hepatitis C, NAFLD (non alcoholic fatty liver disease), and NASH. It is often hard to treat because symptoms are vague and it may be spotted too late to be treated effectively.  
A:
In our last post, we brought up the recent findings on extreme liver cancer growth after successful DAA treatment. We are talking about liver cancer of a few centimetres developed within weeks of successful Hep C treatment. These findings are also observed in patients of Gastroenterology. Dr. Roushdi Khalf allah sai
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us